If you only glanced at Agios Pharmaceuticals’ headlines this year, the story looked upbeat, with EU approval for PYRUKYND in thalassemia and priority FDA review for mitapivat in sickle cell disease. ...
Source LinkIf you only glanced at Agios Pharmaceuticals’ headlines this year, the story looked upbeat, with EU approval for PYRUKYND in thalassemia and priority FDA review for mitapivat in sickle cell disease. ...
Source Link
Comments